The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes

• Published in: Pharmaceuticals (Basel, Switzerland) Switzerland), 2020-11, Vol.13 (12), p.423
• Main Authors: Giudice, Amerigo, Antonelli, Alessandro, Chiarella, Emanuela, Baudi, Francesco, Barni, Tullio, Di Vito, Anna
• Format: Article
• Language: English
• Subjects: Bacteria; Bisphosphonates; exosomes; Gram-positive bacteria; immunity; Infections; inflammation; medication-related osteonecrosis of the jaw (MRONJ); Monoclonal antibodies; oral mesenchymal stem cells; Pathogenesis; Review
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph13120423

Bisphosphonates-related osteonecrosis of the jaw (BRONJ) was firstly reported by Marx in 2003. Since 2014, the term medication-related osteonecrosis of the jaw (MRONJ) is recommended by the American Association of Oral and Maxillofacial Surgeons (AAOMS). Development of MRONJ has been associated to the assumption of bisphosphonates but many MRONJ-promoting factors have been identified. A strong involvement of immunity components has been suggested. Therapeutic intervention includes surgical and non-surgical treatments, as well as regenerative medicine procedures for the replacement of the lost tissues. The literature confirms that the combination of mesenchymal stem cells (MSCs), biomaterials and local biomolecules can support the regeneration/repair of different structures. In this review, we report the major open topics in the pathogenesis of MRONJ. Then, we introduce the oral tissues recognized as sources of MSCs, summing up in functional terms what is known about the exosomes release in physiological and pathological conditions.